Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026)
Jade Biosciences (JBIO) posted Income from Continuing Operations of 40452000.0 for Q1 2026, down 15.65% on a QoQ basis from 34979000.0 in Q4 2025, and down 5.98% year-over-year from 43025480.35 in Q1 2025.
Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Jade Biosciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 40452000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 5.98% year-over-year to 40452000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 202138000.0 (down 58.43% YoY) and the FY2025 annual result came in at 178000.0, up 100.26% from the prior year.
- Income from Continuing Operations was 40452000.0 for Q1 2026 at Jade Biosciences, down from 34979000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10910000.0 in Q1 2022 and bottomed at 118081000.0 in Q1 2024.
- A 5-year average of 43438529.41 and a median of 40452000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 452.25% — and 2025, when it soared 67.68%.
- Jade Biosciences' Income from Continuing Operations stood at 15782000.0 in 2022, then plunged by 40.57% to 22185000.0 in 2023, then plunged by 111.76% to 46979000.0 in 2024, then grew by 25.54% to 34979000.0 in 2025, then fell by 15.65% to 40452000.0 in 2026.
- Business Quant data shows JBIO's Income from Continuing Operations at 40452000.0 in Q1 2026, 34979000.0 in Q4 2025, and 56706000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | -40.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.45 Mn |
| Dec 31, 2025 | -34.98 Mn |
| Sep 30, 2025 | -56.71 Mn |
| Jun 30, 2025 | -70.00 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -46.98 Mn |
| Sep 30, 2024 | -15.57 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | -118.08 Mn |
| Dec 31, 2023 | -22.19 Mn |
| Sep 30, 2023 | -39.12 Mn |
| Jun 30, 2023 | -50.25 Mn |
| Mar 31, 2023 | -60.25 Mn |
| Dec 31, 2022 | -15.78 Mn |
| Sep 30, 2022 | -48.30 Mn |
| Jun 30, 2022 | -43.85 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -48.64 Mn |
| Jun 30, 2021 | -53.21 Mn |